Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
16,657,813
-
Total 13F shares
-
8,048,768
-
Share change
-
+938,479
-
Total reported value
-
$13,279,291
-
Price per share
-
$1.65
-
Number of holders
-
44
-
Value change
-
+$1,503,900
-
Number of buys
-
22
-
Number of sells
-
19
Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q2 2025
As of 30 Jun 2025,
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,048,768 shares.
The largest 10 holders included
Cormorant Asset Management, LP, CITADEL ADVISORS LLC, ACORN CAPITAL ADVISORS, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., DAFNA Capital Management LLC, KENNEDY CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Palo Alto Investors LP, Patient Square Capital LP, and Ikarian Capital, LLC.
This page lists
44
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.